CollPlant Biotechnologies
CLGN
13 hedge funds and large institutions have $7.59M invested in CollPlant Biotechnologies in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
0.13% less ownership
Funds ownership: 12.5% → 12.37% (-0.13%)
17% less capital invested
Capital invested by funds: $9.14M → $7.59M (-$1.55M)
24% less funds holding
Funds holding: 17 → 13 (-4)
67% less call options, than puts
Call options by funds: $1K | Put options by funds: $3K
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Pinnacle Associates
New York
|
+$337K |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$242K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$34.9K |
| 4 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$30.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$25.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$635K |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$148K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$9K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$3.19K |
| 5 |
JP Morgan Chase
New York
|
-$2.37K |
CLGN Hedge Fund Activity: Q1 2024 in Review
13 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q1 2024, worth a combined $7.59M — down 17% from $9.14M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLGN and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 6 added.
The largest buyer was Pinnacle Associates, adding an estimated $337K. The largest seller was Roumell Asset Management, cutting an estimated $635K.
- 13 institutional investors held CollPlant Biotechnologies (CLGN) as of Q1 2024, down from 17 in Q4 2023.
- Funds reported $7.59M of CollPlant Biotechnologies stock for Q1 2024, down 17% quarter-over-quarter.
- 1 fund opened new CollPlant Biotechnologies positions in Q1 2024 and 5 closed out, a net change of -4 holders.
- The largest CollPlant Biotechnologies buyer in Q1 2024 was Pinnacle Associates, an estimated $337K added.
- The largest CollPlant Biotechnologies seller in Q1 2024 was Roumell Asset Management, an estimated $635K sold.
Based on aggregated 13F filings for Q1 2024.